JAMDA
Volume 5, Issue 1 , Pages 47-49 , January 2004

The Appropriate Use of Chemotherapy in Older Adults With Colon Cancer

  • Jerome Goldschmidt, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jerome Goldschmidt, MD, Geriatric Oncology Fellow, c/o Paul Katz, MD, Monroe Community Hospital, 435 E. Henrietta Rd., Rochester, NY 14620.

References 

  1. American Joint Committee on Cancer  . Cancer Staging Handbook . 6th ed.. New York: Springer; 2002;
  2. Edwards  , et al.   Annual Report to the nation of the status of cancer, 1973–1999, featuring implications of age and aging on US cancer burden . Cancer . 2002;94:2766–2792
  3. Sargent  , et al.   A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients . N Engl J Med . 2001;345:1091–1097
  4. Iwashyna, et al. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage iii colon cancer. J Clin Oncol 20: 3992–3998.
  5. Nordin, et al. Psychological reactions in newly diagnosed GI cancer patients. Acta Oncol 36: 803–810.
  6. Schrag, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20: 3999–4005.
  7. Merkel  , et al.   High-risk groups of patients with stage II colon carcinoma . Cancer . 2001;92:1435–1443
  8. Guidelines available online at: www.nccn.org/physician_gls/f_guidelines.html
  9. Casciato DA , Lowitz BB . Manual of Clinical Oncology . 4th ed.. Philadelphia: Lippincott Williams and Wilkins; 2000;
  10. Tope  , et al.   Psycho-oncology: Psychological well-being as one component of quality of life . Psychother Psychosom . 1993;60:129–147
  11. E Greenwald. Organic mental changes with fluorouracil therapy [Letter]. JAMA 235.
  12. Silberfarb  , et al.   Chemotherapy and cognitive defects in cancer patients . Annu Rev Med . 1983;34:35–46
  13. Figueredo, et al. Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant chemotherapy for resected colorectal cancer. Cancer Invest 13: 608–611.
  14. van Dam, et al. Impairment of cognitive function in women receiving adjuvant treatment for high risk breast cancer: High dose vs. standard dose chemotherapy. J Natl Cancer Inst 90: 210–218.
  15. Shagen, et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast cancer. Cancer 85: 640–650.
  16. Ahles, et al. Neuropsychological impact of standard dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20: 485–493.

PII: S1525-8610(04)70043-2

JAMDA
Volume 5, Issue 1 , Pages 47-49 , January 2004

Article Tools